Behzad Aghazadeh disclosed a 16.37% beneficial stake in Scribe Therapeutics, Inc. through funds managed by Avoro. The Schedule 13D, filed on Jul. 30, 2026, follows Scribe’s IPO pricing on July 23 and closing on July 27, 2026. The position includes IPO purchases, converted preferred shares, and open-market buys, and Aghazadeh currently serves on Scribe’s board.
Investor Intent
Avoro and Aghazadeh state they hold Scribe shares "for investment purposes," and Aghazadeh serves on the company’s board of directors. He may also receive director compensation, including equity awards, under Scribe’s non-employee director policy.
The funds agreed to a 180-day lock-up from the IPO, which Scribe extended to September 28, 2026, with exceptions that allow sales of shares bought in the IPO or in open-market trades after the offering. They also waived registration rights for the IPO and delayed demand registration rights until 180 days after the IPO’s effective date.
Investor's Background
Avoro Capital Advisors LLC is a Delaware-registered investment adviser that manages Avoro Life Sciences Fund and related vehicles. The firm, led by portfolio manager and controlling person Behzad Aghazadeh, focuses on biotechnology and healthcare investments with a history of active engagement. Aghazadeh is known for significant biotech campaigns, including high-profile involvement with Immunomedics.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.